Roche trial of drug to treat COVID-19-related pneumonia fails


ZURICH, July 29 (Reuters) - A late-stage clinical trial of Roche's ROG.S Actemra/RoActemra drug to treat patients hospitalised with severe COVID-19-related pneumonia failed, the drugmaker said on Wednesday.

The "COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality," Roche said.

(Reporting by John Revill; Editing by Michael Shields)

((; +41 58306 7022; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.